Be the first to like this
IntroductionMCI is a borderline condition between normal aging and dementia affecting around 23.4 million subjects across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) in 2007, 37% of whom were suffering from prodromal Alzheimer's disease. MCI-specific annual sales are expected to increase seven-fold from 2007 to $3.3 billion across the seven major markets by 2018.Scope*Definition and prevalence of MCI and its major sub-types.*Review of the key unmet needs in the treatment of the MCI subtypes as identified by key opinion leaders.*MCI-specific drug sales value and number of treated patients forecasts to 2018 in the US, Japan, and five major European markets.*Pipeline analysis with detailed profiles for key late-stage drugs potentially appropriate for MCI patients.HighlightsDriven by off-label sales of several products currently in development for Alzheimer's disease, MCI-specific annual sales are expected to increase seven-fold from 2007 to $3.3 billion across the seven major markets by 2018.Although Datamonitor anticipates growth in the number of treated MCI patients (2.3% in 2007 rising to 4.27% in 2018), the treatment rate will remain hampered by the slow uptake of relatively expensive diagnostic tools and lack of marketing authorization for drugs within the forecast period.In the long-term, Datamonitor believes that MCI will become a viable indication expansion opportunity for companies marketing dementia drugs. However, the current marketed drugs for Alzheimer's disease are not appropriate, and new drugs for dementia are still a few years from the market.Reasons to Purchase*Better understand the concept of MCI and its limits in the identification of the syndromes sub-types and the approval of treatments.*Quantify the MCI-specific market to 2018 in the US, Japan, and five major European markets and identify the drivers and resistors in this market.*Understand unmet needs and opportunities in the definition, diagnosis and management of MCI based on key opinion leader comments.